Mansoura University
Al Mansurah, Egypt
NCT Number: NCT06901323
Effect of L-carnitine supplementation on phenylalanine and brain-derived neurotrophic factor levels in infants and children with phenylketonuria
L-carnitine is mainly obtained from foods such as red meat and milk that are limited for PKU patients due to dietary protein restriction. So, L-carnitine deficiency has been described in phenylketonuric patients
The aim of this study is to :
1. Compare level of Brain-derived neurotrophic factor in infants and children with phenylketonuria and healthy infants and children. 2. Compare level of phenylalanine and Brain-derived neurotrophic factor before and after L-carnitine supplementation in phenylketonuric patients. 3. Assess Intelligence quotient test before and after L-carnitine supplementation in phenylketonuric patients
This study is active but is not currently recruiting participants.
Notify Me1 month–18 year
All sexes
Interventional
Phase 4
Al Mansurah, Egypt
Subjects And Methods :
1- Cross sectional comparative study ( PKU versus non PKU infants and children).
2- Open label Randomized controlled clinical trial for PKU patients only.
1-Male and female PKU patients diagnosed and following up at Genetics and Metabolic Outpatient Clinic.
2- Age from one month up to 18 years.
1- Intervention group: Forty four patients will treated with L-carnitine at a dose of 100 mg/kg/dose for one year beside their traditional treatment.
2- Control PKU group: Forty four patients will not receive L-carnitine supplementation beside their traditional treatment.
3- Control healthy group: Eighty eight healthy infant and child with matched age and sex.
Block randomization with block size of 4 and 22 blocks using opaque sealed envelop.
Investigations:
b - Psychological assessment:
samples collection: For this study 5 ml whole blood samples will be collected from patients diagnosed with Phenylketonuria at Genetics and Metabolic outpatients clinic of MUCH. The plasma/serum will be separated and utilized to measure levels of phenylalanine and BDNF level by ELISA in clinical pathology lab of faculty of medicine - Mansoura university.
Statistical analysis:
The collected data will be coded, processed and analyzed using SPSS program (Version 29) .
The appropriate statistical tests will be used when needed. P values less than 0.05 (5%) will be considered to be statically significant.
Ethical consideration:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
44 patients diagnosed as a case of phenylketonuria will receive l-carnitine at a dose of 100 mg/kg/day for 1 year and then blood sample will examined for level of brain-derived neurotrophic factor levels before and after therapy and another group composed of 44 patients diagnosed as a case of phenylketonuria will not receive l-carnitine and their blood sample will examined for level of brain-derived neurotrophic factor levels treated and untreated patients will compared with healthy children and infants has same age and sex .
Time frame: 1 year
Mansoura University
Other
Effect of L-carnitine Supplementation on Phenylalanine and Brain-derived Neurotrophic Factor Levels in Infants and Children With Phenylketonuria Two Phases Study 1- Cross Sectional Comparative Study ( PKU Versus Non PKU Infants and Children). 2- Open Label Randomized Controlled Clinical Trial for PKU Patients Only. 1/ Intervention Group: 44 Patients Will Treated With L-carnitine at a Dose of 100 mg/kg/Dose for One Year Beside Their Treatment. 2/ Control PKU Group: 44 Patients Will Not Receive L-carnitine Supplementation Beside Their Treatment 3/ Control Healthy Group Same Age and Sex
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05166161
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Aurora, Colorado, United States
View Trial DetailsNCT06780332
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Chevy Chase, Maryland, United States
View Trial DetailsNCT05972629
Amino Acid Metabolism, Inborn Errors, Brain Diseases
San Francisco, California, United States
View Trial DetailsNCT07241234
Amino Acid Metabolism, Inborn Errors, Brain Diseases
Indianapolis, Indiana, United States
View Trial Details